CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 7 enrolled
Drug / intervention
Granulocyte Colony Stimulating Factor (GCSF)drug
Likely dose
Granulocyte Colony Stimulating Factor (GCSF) 10mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01538862
NCT01538862Phase 2Completed
CompareCT.gov

Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa

Vanderbilt University Medical Center·interventional·Posted Feb 24, 2012·Updated Jun 23, 2017

In Brief

A Phase 2 clinical trial evaluating Granulocyte Colony Stimulating Factor (GCSF) for Dystrophic Epidermolysis Bullosa. Completed, enrolled 7 participants across 1 site.

Detailed Summary

This is a feasibility study to see if Granulocyte Colony Stimulating Factor (GCSF) is effective as a treatment of Dystrophic Epidermolysis Bullosa (EB). Patients will receive one course of treatment with the study drug. The course will be 7 days in length. After receiving GCSF, patients will be followed at 7 and 30 days following the discontinuation of the drug. Thirty day follow up can be done via telephone communication with the patient or family.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDystrophic Epidermolysis Bullosa
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 24, 2012
Enrollment StartFeb 1, 2012
Primary CompletionOct 1, 2014
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 14.4 years ago

Interventions

Granulocyte Colony Stimulating Factor (GCSF)drug

G-CSF 10mcg/kg/d SQ for 7 days